21st International Congress » Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

1:15pm-2:45pm

5-year results from the NSTAPS trial: comparing bilateral deep brain stimulation of the globus pallidus pars interna versus the subthalamic nucleus for advanced Parkinson’s disease.

J. Boel, V. Odekerken, P. vanden Munckhof, G. Geurtsen, M. Figee, J. Dijk, R. de Haan, B. Schmand, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

1:15pm-2:45pm

A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients

K.R. Chaudhuri, A. Antonini, W. Poewe, D. Standaert, P. Odin, J. Zamudio, L. Bergmann (London, United Kingdom)

1:15pm-2:45pm

A novel paradigm of variable frequency deep brain stimulation to improve freezing of gait in Parkinson’s disease

F. Jia, A. Wagle Shukla, w. Hu, L. Almeida, M. Okun, L. Li (Beijing, China)

1:15pm-2:45pm

A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update

K. Biglan, J. Lowell, D. Oakes, K. Hodgeman, R. Rockhill, B. Greco, R. Holloway, T. Simuni (Rochester, NY, USA)

1:15pm-2:45pm

A Preliminary Study: Validity and Reliability of Parkinson Fatigue Scale (PFS) in Turkish Patients with Parkinson’s Disease (PD)

E. Ozturk, E. Ozturk, B. Gonenli Kocer, I. Gundogdu, A. Cakci, E. Umay (Ankara, Turkey)

1:15pm-2:45pm

A Preliminary Study: Validity and Reliability of Turkish Version of Fatigue Severity Scale (FSS) in Patients with Parkinson’s Disease (PD)

E. Ozturk, B. Gonenli Kocer, I. Gundogdu, A. Cakci, E. Umay (Ankara, Turkey)

1:15pm-2:45pm

A prospective comparison of apomorphine, STN deep brain stimulation and levodopa-carbidopa intestinal gel therapy for motor fluctuations in PD

H.-L. Chiang, F. Chang, D. Tsui, Y. Tai, A. Ha, N. Mahant, J. Griffith, D. Galea, S. Kim, B. Cruse, H. Morales-Briceño (New Taipei City, Taiwan)

1:15pm-2:45pm

A prospective randomized cross-over study of telemedicine system in Parkinson’s disease

S. Sekimoto, G. Oyama, T. Hatano, F. Sasaki, R. Nakamura, T. Jo, Y. Shimo, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm

A single aerobic exercise session of treadmill increases BDNF levels in Parkinson’s disease patients

P. Scalzo, L. Dos Santos, J. Pereira, R. Santos, N. Rocha, A. Texeira, P. Christo (Belo Horizonte, Brazil)

1:15pm-2:45pm

Acquisition, Validation and Preprocessing of Wrist-Worn Sensor Data in Patients with Parkinson’s Disease and Healthy Controls

D. Pichler, M. Lang, D. Kulić, F. Pfister, G. König, T. Um, A. Ahmadi, S. Endo, F. Achilles, K. Abedinpour, K. Bötzel, A. Ceballos-Baumann, S. Hirche, U. Fietzek (Munich, Germany)

1:15pm-2:45pm

Active Arms: a randomized controlled trial of an interactive videogame for people with Parkinson’s disease

N. Allen, J. Song, S. Paul, S. Smith, J. O'Duffy, M. Schmidt, R. Love, C. Sherrington, C. Canning (Lidcombe, Australia)

1:15pm-2:45pm

Aerobic Exercise Combined with rTMS for Parkinson’s Disease: A Randomized Trial

H. Migdadi, M. Biagioni, S. Agarwal, A. Cucca, P. Kumar, A. Quartarone, R. Rossi, M. Ghilardi, A. Di Rocco (New York, NY, USA)

1:15pm-2:45pm

Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson’s Disease

C.-M. Chen, K.-H. Chang, Y.-R. Wu, M.-L. Cheng (Taoyuan, Taiwan)

1:15pm-2:45pm

Ambulatory movement measurement in evaluating deep brain stimulation effect in patients with advanced Parkinson’s disease

M. Koivu, F. Scheperjans, E. Pekkonen (Helsinki, Finland)

1:15pm-2:45pm

Antiparkinson and antioxidant effect of N-Methanesulfonylpyrazolinyl substituted Heterosteroids in LPS induced Neuroinflammation Model of Rats

R. Singh (Chandigarh, India)

1:15pm-2:45pm

Aquatic Physical Exercises: Balance in People with Parkinson’s Disease

M. Ferreira, B. Yamaguchi, A. Silva, V. Israel (Curitiba, Brazil)

1:15pm-2:45pm

Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study

C. Kenney, A. Glass, W. Olanow (Ardsley, NY, USA)

1:15pm-2:45pm

Automated dosing schemes for administration of microtablets of levodopa for Parkinson’s disease, using wearable sensors

I. Thomas, F. Bergquist, D. Johansson, D. Nyholm, M. Memedi, J. Westin (Falun, Sweden)

1:15pm-2:45pm

Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD

W. Olanow, A. Ellenbogen, R. Djaldetti, T. Rachmilewitz Minei, Y. Cohen, S. Oren, K. Kieburtz (New York, NY, USA)

1:15pm-2:45pm

Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)

R. Postuma, J. Anang, A. Pelletier, M. Moscovich, D. Grimes, A. Borys, S. Furtado, R. Munhoz, S. Cresswell, A. Moro, D. Hobson, L. Joseph, A. Lang (Montreal, QC, Canada)

1:15pm-2:45pm

Comparison of hand functions between people with Parkinson’s disease and healthy subjects

M. Mak, I. Wong (Hong Kong, Hong Kong)

1:15pm-2:45pm

DBS Plus: Investigating cell therapy and deep brain stimulation as an approach to alter disease progression and treat motor and non-motor symptoms of Parkinson’s disease

C. van Horne, J. Quintero, J. Gurwell, A. Anderson-Mooney, A. Welleford, J. Lamm, J. Slevin, G. Gerhardt (Lexngton, KY, USA)

1:15pm-2:45pm

Decision-making process for opicapone’s bedtime regimen

A. Falcão, A. Santos, J. Ferreira, A. Lees, B. Hernandez, F. Rocha, P. Soares-da-Silva (Coimbra, Portugal)

1:15pm-2:45pm

Deep brain stimulation in Parkinson’s disease: Outcome after more than nine years

B. Thomsen, S. Jensen, A. Clausen, B. Jespersen, M. Karlsborg, A. Løkkegaard (Copenhagen, Denmark)

1:15pm-2:45pm

Deep Learning in Objective Classification of Spontaneous Movement of Patients with Parkinson’s Disease Using Large-Scale Free-Living Sensor Data

F. Pfister, D. Kulić, T. Um, D. Pichler, A. Ahmadi, M. Lang, G. König, F. Achilles, S. Endo, K. Abedinpour, K. Ziegler, K. Bötzel, S. Hirche, A. Ceballos-Baumann, U. Fietzek (Munich, Germany)

1:15pm-2:45pm

Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study

H. Fernandez, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, R. Hauser (Cleveland, OH, USA)

1:15pm-2:45pm

Disease-modifying effect of Zonisamide with the induction of BDNF and TrkB expression

N. Kanzato (Haebaru-cho, Japan)

1:15pm-2:45pm

Does the side of onset affect motor and non-motor symptoms in Parkinson’s disease?

J. Silva, A. D'Abreu (Campinas, Brazil)

1:15pm-2:45pm

Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment

R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, R. Chaudhuri, T. Henriksen, T. van Laar, K. Spivey, S. Vel, A. Lees (Vienna, Austria)

1:15pm-2:45pm

Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study

S. Sharma, T. Simuni, B. Greco, K. Biglan, C. Tarolli, K. Hodgeman, D. Oakes, D. Penz (Rochester, NY, USA)

1:15pm-2:45pm

Early morning OFF problems are common in PD patients attending a routine clinical appointment

F. Stocchi, C. Coletti, S. Bonassi, L. Vacca (Rome, Italy)

1:15pm-2:45pm

Effect of deep brain stimulation on visuospatial impairment in Parkinson’s disease

Y. Okahara, Y. Higuchi, K. Aoyagi, M. Abe, T. Yamamoto, Y. Yamanaka, S. Hirano, Y. Iwadate (Chiba, Japan)

1:15pm-2:45pm

Effect of food on Opicapone pharmacokinetics and pharmacodynamics

A. Santos, A. Falcão, J. Ferreira, A. Lees, B. Hernandez, F. Rocha, P. Soares-da-Silva (S. Mamede Coronado, Portugal)

1:15pm-2:45pm

Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients

A. Antonini, W. Poewe, D. Standaert, C. Zadikoff, S. Dubow, L. Bergmann, A. Yegin, C. Hall, W. Robieson, V. Felipe, L. Barbato (Venice, Italy)

1:15pm-2:45pm

Effect Of Non-Invasive Vagus Nerve Stimulation In Freezing And Oxidative Stress In Parkinson’s Disease Patients

B. MONDAL, S. CHOUDHURY, G. PAUL, M. MONDAL, M. BAKER, K. CHATTERJEE, P. CHATTERJEE, R. BANERJEE, R. SINGH, H. KUMAR (KOLKATA, India)

1:15pm-2:45pm

Effects of a Aquatic Dual Task Activity Program on the Quality of Life and Activities of Daily Living in Individuals with Parkinson’s Disease

A. Silva, V. Israel (Curitiba, Brazil)

1:15pm-2:45pm

Effects of a Parkinson-Specific, Interdisciplinary Approach, To Inpatient Rehabilitation

C. Benedict, D. Fredericks, C. Manganiello, H. Herrstrom, D. Schmitt, K. Lyons (Topeka, KS, USA)

1:15pm-2:45pm

Efficacy and Safety of Therapeutic Interventions to Treat Motor Symptoms in Late Stage Parkinson’s Disease: A Systematic Review

M. Coelho, K. Destri, M. Fabbri, A. Schrag, J. Ferreira, b.C. Consortium (Lisbon, Portugal)

1:15pm-2:45pm

Efficacy of rotigotine as measured by individual Unified Parkinson’s Disease Rating Scale II and III items: a post-hoc analysis

M. Asgharnejad, H. Pesch, E. Dohin (Raleigh, NC, USA)

1:15pm-2:45pm

Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease:  results from the Phase 3 study dose-titration phase

R. Hauser, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, H. Fernandez (Tampa, FL, USA)

1:15pm-2:45pm

Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease

P. Lingor, A. Leha, B. Michalke, M. Börger, M. Bähr, I. Zerr, F. Maass (Göttingen, Germany)

1:15pm-2:45pm

Evaluation of rotigotine transdermal patch in combination with low or high dose levodopa in patients with Parkinson’s disease: post-hoc analysis

E. Dohin, F. Woltering, M. Asgharnejad (Brussels, Belgium)

1:15pm-2:45pm

Exergaming in Patients with Parkinson’s Disease

C. Gemin, L. da Silva, M. Ribas Corrêa, H. Ghizone Teive, S. Valderramas (Curitiba, Brazil)

1:15pm-2:45pm

Factors associated with perceived walking difficulties in people with Parkinson’s disease

M. Kader, S. Ullén, S. Iwarsson, P. Odin, M. Nilsson (Lund, Sweden)

1:15pm-2:45pm

Feasibility of using a smartphone application for the objective evaluation of Parkinson disease

R. Schneider, J. Adams, M. Elson, C. Tarolli, S. Sharma, A. Glidden, T. Felong, A. Zhan, R. Korn, S. Goldenthal, D. Harris, M. Xiong, M. Little, K. Biglan, R. Dorsey (Rochester, NY, USA)

1:15pm-2:45pm

Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study

T. Simuni, C. Caspell-Garcia, N. Seedorff, C. Coffey, S. Lasch, B. Mollenhauer, C. Tanner, K. Kieburtz, K. Marek (Chicago, IL, USA)

1:15pm-2:45pm

Focused ultrasound subthalamotomy for Parkinson’s disease: A pilot study

R. Martinez-Fernandez, R. Rodriguez-Rojas, M. del Álamo, F. Hernandez, J.A. Pineda-Pardo, M. di Leone, F. Alonso, I. Obeso, C. Gasca-Salas, E. de Luis, L. Vela, J.A. Obeso (Mostoles, Spain)

1:15pm-2:45pm

Four year outcomes of a prospective, multi-center trial evaluating Deep Brain Stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease

L. Timmermann, R. Jain, N. Van Dyck, L. Chen, T. Brücke, F. Seijo, E. San Martin, V. Visser-Vandewalle, M. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Cologne, Germany)

1:15pm-2:45pm

Gait Asymmetry and Parkinson’s Disease

C. Ashton, L. Solis-Cohen, L. Wagenaar, R. Laracuente, E. Sorberg, V. Vanderhorst, L. Shih (Boston, MA, USA)

1:15pm-2:45pm

Home-based step training using videogame technology in people with Parkinson’s disease: a randomized controlled trial

J. SONG, S. Paul, M.J. Caetano, S. Smith, L. Dibble, R. Love, D. Schoene, J. Menant, C. Sherrington, S. Lord, C. Canning, N. Allen (Ultimo, NSW, Australia)

1:15pm-2:45pm

How to switch from Entacapone to Opicapone based on BIPARK-I study experience

J. Ferreira, A. Lees, A. Santos, B. Hernandez, F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:15pm-2:45pm

How will new technology change deep brain stimulation programming?

G. Duffley, A. Schiewe, B. Lutz, J. Krüger, M. Okun (Salt Lake City, UT, USA)

1:15pm-2:45pm

Identification of the optimal carbidopa concentration in subcutaneously administered ND0612

L. Adar, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

1:15pm-2:45pm

Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life

D. Standaert, R. Rodriguez, J. Slevin, M. Lobatz, C. Hall, M. Facheris, J. Benesh, S. Dubow (Birmingham, AL, USA)

1:15pm-2:45pm

Improvement on gait in Parkinson’s disease patients using Honda stride management assist device

N. Kawashima, M. Matsuhashi, T. Hamano, K. Nagami, T. Furukado, M. Iijima, M. Isogai, M. Komachi, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

1:15pm-2:45pm

Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation

K. Schroeder, M. Fenney, D. Gray, T. Rolph, S. Sohur, V. Todaro (New York, NY, USA)

1:15pm-2:45pm

Improving Racial and Ethnic Diversity in Parkinson`s Disease Clinical Trials

S. Ray, A. Madan, D. Burdick, A. Griffith, P. Agarwal (Kirkland, WA, USA)

1:15pm-2:45pm

Innovative recruitment strategies accelerate enrollment of genetic mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI)

V. Arnedo, S. Lasch, T. Foroud, L. Heathers, J. Martorelli, C. Halter, N. Ryerson, J. Verbrugge, L. Cook, K. Marek (New York, NY, USA)

1:15pm-2:45pm

Intensive Short-Term Dance Intervention in Parkinson’s Disease

D. Rabinovich, J. DeSouza, T. Arakaki, S. Rodriguez Quiroga, V. Litvak, J. Firmani, N. Garreto (Toronto, ON, Canada)

1:15pm-2:45pm

INTREPID Trial: A Prospective, Double blinded, Multi-center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple-Source, Constant-Current Rechargeable System in Parkinson’s Disease

J. Vitek, R. Jain, P. Starr (Minneapolis, MN, USA)

1:15pm-2:45pm

Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease

A. Negida, Z. Hassan, H. Ahmed, O. Hassan, A. Elsherbiny, S. Azzam, O. Osama, Y. Ibrahim (Zagazig, El-Sharkia, Egypt)

1:15pm-2:45pm

Istradefylline for daytime sleepiness and sleep disturbances in patients with Parkinson’s disease: an open-label, 3-month study

K. Suzuki, M. Miyamoto, T. Miyamoto, T. Uchiyama, Y. Watanabe, T. Kadowaki, K. Hirata (Mibu, Japan)

1:15pm-2:45pm

Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.

K. Ohta, Y. Kujuro, T. Osada (Tokyo, Japan)

1:15pm-2:45pm

Levodopa effect and motor function in late stage Parkinson’s disease

K. Rosqvist, P. Odin, M. Horne, P. Hagell, S. Iwarsson, M. Nilsson (Lund, Sweden)

1:15pm-2:45pm

Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study

N. Kovacs, A. Juhász, Z. Aschermann, P. Ács, J. Janszky, M. Kovács, A. Makkos, M. Harmat, D. Tényi, K. Katádi, S. Komoly, A. Takáts, A. Tóth, H. Nagy, P. Klivényi, G. Dibó, L. Dézsi, D. Zádori, Á. Annus, L. Vécsei, L. Varannai (Pécs, Hungary)

1:15pm-2:45pm

Long-Term Dopamine Transporter Imaging and Clinical Effects of the Mixed-Lineage Kinase Inhibitor CEP-1347 in the PRECEPT Parkinson Trial

I. Shoulson, S.E. Eberly, D. Oakes, A. Lang, M. Schwarzschild, C. Tanner, J. Seibyl, K. Marek (Washington, DC, USA)

1:15pm-2:45pm

Manual and Verbal guidance during the balance training based in virtual reality is essential for therapeutic results in people with Parkinson’s disease: a randomized clinical trial

M.E. Pimentel Piemonte, A. Falconi, M. D"Alencar, E. Okamoto (Sao Paulo, Brazil)

1:15pm-2:45pm

Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series

D.H. Kim, D.H. Kim, J.J. Choi, B.J. Park (Daejeon, Republic of Korea)

1:15pm-2:45pm

Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study

M. Stacy, V. Biton, J. Aldred, A. Ellenbogen, R. Rubens, N. Modi, A. Mittur, S. Khanna, S. Gupta (Durham, NC, USA)

1:15pm-2:45pm

Movement disorder specialists’ determination of eligibility for device aided treatment in advanced Parkinson’s disease: Results from the OBSERVE-PD study

A. Fasano, K. Seppi, V.SC. Fung, J.C. Parra, L. Bergmann, A. Yegin, K. Sail, Y. Jalundhwala, K. Onuk (Toronto, ON, Canada)

1:15pm-2:45pm

Moxibustion for Parkinson’s disease: a systematic review of randomized controlled trials

T.-H. Kim, S. Kwon, W.-S. Jung, S.-K. Moon, C.-N. Ko, S.-Y. Cho, C.-Y. Jun, S.-H. Lee, K.-H. Cho (Seoul, Republic of Korea)

1:15pm-2:45pm

Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

1:15pm-2:45pm

ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD

N. Giladi, Y. Caraco, T. Gurevich, R. Djaldetti, L. Adar, T. Rachmilewitz Minei, S. Oren (Tel Aviv, Israel)

1:15pm-2:45pm

ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data

L. Adar, C. Durlach, O. Yacoby Zeevi, D. Fishelovitch, S. Oren (Rehovot, Israel)

1:15pm-2:45pm

Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, M. Hebron, Y. Torres-Yaghi, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, A. Shekoyan, J. Ahn, C. Moussa (Washington, DC, USA)

1:15pm-2:45pm

Noladin ether attenuates MPTP -induced motor deficit by abrogating pro-inflammatory cytokines and striatal neurochemical alterations in rats

R. Deshmukh, S. Singh (Moga, India)

1:15pm-2:45pm

Observational study of the effectiveness and tolerability of rotigotine+levodopa therapy in older vs younger Parkinson’s disease patients

D. Woitalla, M. Asgharnejad, L. Joeres, J.-C. Schuller, K.R. Chaudhuri (Bochum, Germany)

1:15pm-2:45pm

ON-time evolution following one-year open-label opicapone: BIPARK-I study

J. Ferreira, A. Lees, O. Rascol, W. Poewe, A. Santos, I. Oliveira, B. Hernandez, F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:15pm-2:45pm

Open label study of cannabidiol in Parkinson disease

M. Leehey, Y. LIU, C. EPSTEIN, F. HART, J. BAINBRIDGE, M. COOK, S. SILLAU, Z. BAUD, H. NEWMAN (AURORA, CO, USA)

1:15pm-2:45pm

Outcomes of a Prospective, Multicenter International Registry of Deep Brain Stimulation for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, A. Kühn, L. Timmermann, M. Pötter-Nerger, P. Eldridge, J. Volkmann, J. Fitzgerald, A. Schnitzler, H. Mehdorn, J. Vesper (Kiel, Germany)

1:15pm-2:45pm

Patient Engagement in Parkinson’s Research: A Comparison of Attitudes and Impact in the UK and the US

V. Todaro, C. Nolan, K. Schroeder, I. Abbey-Vital, M. Feeney (New York, NY, USA)

1:15pm-2:45pm

Patient perspectives of using the ND0612 mini-pump

S. Nash, M. Gera, E. Shor, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

1:15pm-2:45pm

Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)

L. Adar, T. Rachmilewitz Minei, Y. Cohen, S. Oren (Rehovot, Israel)

1:15pm-2:45pm

Physical activity habits in early Parkinson’s disease and healthy controls

A. Amara, N. Seedorff, L. Chahine, K. Kieburtz, C. Caspell-Garcia, T. Simuni (Birmingham, AL, USA)

1:15pm-2:45pm

Post-hoc analyses of the recommended starting dose for Rytary based on “off” time

N. Modi, S. Khanna, S. Gupta (Hayward, CA, USA)

1:15pm-2:45pm

Postural Instability is a Predictor for Driving Cessation Among Parkinson’s Disease Drivers: A Study of a Computer-Based 3D Driving Simulator.

O. Jitkritsadakul, S. Krootjohn, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:15pm-2:45pm

Preliminary Report on the MAESTRO Study: A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease.

S. Ray, D. Burdick, A. Griffith, P. Agarwal (Kirkland, WA, USA)

1:15pm-2:45pm

Preventing Levodopa Induced Dyskinesia with Docosohexanoid Acid in Parkinson Disease

K. Chung, B. Lobb (Portland, OR, USA)

1:15pm-2:45pm

Prognosis and end-of-life status after emergency admissions in patients with Parkinson disease: a Japanese single center retrospective study

K. Ikeda, K. Takahashi, K. Kawasaki, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Araki, T. Yamamoto (Iruma-gun, Saitama-ken, Japan)

1:15pm-2:45pm

Programming of deep brain stimulators in Parkinson’s disease with early motor complications (EARLYSTIM-study)

K. Knudsen, J.-L. Houeto, P. Krack, J. Rau, C. Schade-Brittinger, A. Schnitzler, W.M.M. Schuepbach, L. Timmermann, L. Tonder, G. Deuschl (Kiel, Germany)

1:15pm-2:45pm

Proprioceptive Focal Stimulation (Equistasi®) may improve gait in severe Parkinson’s disease patients. Gait Analysis double-blind, double-dummy randomized study

A. Peppe, S. Paravati, g. Chini, P. Paone (Roma, Italy)

1:15pm-2:45pm

Quantitative demonstration of the efficacy of rotigotine transdermal patch in the treatment of nocturnal hypokinesia: A randomized, placebo-controlled trial using an axial inertial sensor

R. Bhidayasiri, J. Sringean, S. Chaiwong, C. Anan, K. Boonpang, K. Sakdisornchai, O. Jitkritsadakul, P. Jagota (Bangkok, Thailand)

1:15pm-2:45pm

Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.

T.G. Study Group (Bristol, United Kingdom)

1:15pm-2:45pm

Real World Clinical Outcomes Using a Novel Directional Lead from a Multicenter Registry of DBS for Parkinson’s disease

G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, M. Pötter-Nerger, L. Timmermann, J. Volkmann, A. Kühn, P. Eldridge, J. Fitzgerald, H. Mehdorn, J. Vesper (Kiel, Germany)

1:15pm-2:45pm

Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease

J. Jankovic, I. Goodman, B. Safirstein, D. Schenk, G. Kinney, M. Koller, D. Ness, S. Griffith, M. Grundman, J. Soto, S. Ostrowitzki, F. Boess, M. Martin-Facklam, J. Quinn, S. Isaacson, D. Jennings, O. Omidvar, A. Ellenbogen (Houston, TX, USA)

1:15pm-2:45pm

Safety of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients receiving ≥ 2000 mg daily dose of levodopa

C. Zadikoff, J. Boyd, S. Dubow, L. Bergmann, W. Robieson, H. Ijacu, J. Benesh (Chicago, IL, USA)

1:15pm-2:45pm

Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study

S. Isaacson, R. Hauser, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinksi, B. Dzyngel, A. Agro, H. Fernandez (Boca Raton, FL, USA)

1:15pm-2:45pm

Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study

T. Simuni, C. Caspell-Garcia, N. Seedorff, C. Coffey, S. Lasch, B. Mollenhauer, C. Tanner, K. Kieburtz, K. Marek (Chicago, IL, USA)

1:15pm-2:45pm

Sentence comprehension in Slovak speaking patients with Parkinson´s disease – preliminary results

A. Kušnírová, J. Marková, Z. Košutzká, M. Egryová, M. Pápayová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)

1:15pm-2:45pm

Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).

C. Olanow, K. Kieburtz, N. Livnah (New York, NY, USA)

1:15pm-2:45pm

Social importance of care and rehabilitation in restoring of psycho-emotional and movement deficits in Parkinsonism.

M. Sanoeva, M. Gulova, M. Avezova, N. Mansurova (Bukhara, Uzbekistan)

1:15pm-2:45pm

Spinal cord stimulation as therapeutic option in gait disorder in Parkinson disease.

H. Cécile, D'H. Vincent, B.M. MALEK, p.-k. nathalie, t. Jean-Batiste, Z. MARC, B. Jean-Philippe (PARIS, France)

1:15pm-2:45pm

Study Design for a Multi-Modal Approach to Understanding Parkinson’s Disease: The Personalized Parkinson Project

W. Marks, Jr., L. Evers, M. Faber, M. Verbeek, N. de Vries, B. Bloem (South San Francisco, CA, USA)

1:15pm-2:45pm

Study Design of an Efficacy and Safety Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of APL-130277 in the Treatment of OFF Episodes (CTH-300)

C.W. Olanow, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro (New York, NY, USA)

1:15pm-2:45pm

Study in Parkinson’s Disease of Exercise (SPARX): A Randomized, Controlled Futility Trial

D. Corcos, C. Moore, W. Kohrt, D. Hall, A. Delitto, C. Comella, D. Josbeno, C. Christiansen, B. Berman, B. Kluger, E. Melanson, S. Jain, J. Robichaud, C. Poon, M. Schenkman (Chicago, IL, USA)

1:15pm-2:45pm

Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis

M. Hacker, M. Turchan, A. Currie, L. Heusinkveld, S. Millan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)

1:15pm-2:45pm

Tandem Standing

E. Okuyucu, E. Dogru Huzmeli, S. Colakoglu Yesildag, I. Huzmeli (Hatay, Turkey)

1:15pm-2:45pm

The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine

K. Romero, D. Conrado, B. Corrigan, K. Tsai, M. Ahamadi, S. Macha, V. Sinha, I. Watson, M. Bani, P. Muglia, V. Kern, C. Williams-Gray, D. Grosset, M. Hu, D. Burn, R. Lawson, K. Marek, A. Roach, D. Stephenson, T. Nicholas (Tucson, AZ, USA)

1:15pm-2:45pm

The effect of dance and Nordic Walking on balance, gait and motor function in Parkinson’s disease

J. Stożek, M. Rudzińska, I. Staszczak-Gawełda, A. Stenwak, K. Świątek, S. Podsiadło, U. Pustułka-Piwnik, A. Szczudlik (Krakow, Poland)

1:15pm-2:45pm

The effect of early STN-DBS in PD patients on axial symptoms: a 2-year randomized controlled trial (EARLYSTIM-Gait analysis)

M. Barbe, L. Tonder, F. Sixel-Döring, B. Debû, L. Timmermann, A. Schnitzler, C. Schade-Brittinger, J. Rau, P. Krack, J.-L. Houeto, M. Schüpbach, G. Deuschl (Cologne, Germany)

1:15pm-2:45pm

The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease

M. Nagai, M. Kubo, H. Iwaki, R. Ando, M. Nomoto (Ehime, Japan)

1:15pm-2:45pm

The Importance of Ultrasonographic Evaluation in the Diagnosis of Dysphagia in Parkinson Disease

E. Umay, E. Ozturk, I. Gundogdu, O. Delibas, B. Gonenli, A. Cakci (Ankara, Turkey)

1:15pm-2:45pm

The landscape of interventional trials in Parkinson disease: A 10-year review of ClinicalTrials.gov between 2006 and 2016

K. Wyant, E. Yasuda, V. Kotagal (Ann Arbor, MI, USA)

1:15pm-2:45pm

The occurrence of dopamine-responsive and dopamine-resistant resting tremor in Parkinson’s disease

H. Zach, M. Dirkx, D. Roth, j. Pasman, B. Bloem, R. Helmich (Nijmegen, Netherlands)

1:15pm-2:45pm

Towards Responsive Deep Brain Stimulation for Medically Refractory Freezing of Gait in Parkinson’s Disease

R. Molina, J. Shute, E. Opri, K. Sowalsky, J. Roper, D. Martinez-Ramirez, K. Foote, C. Hass, M. Okun, A. Gunduz (Gainesville, FL, USA)

1:15pm-2:45pm

Tozadenant phase 3 study (TOZ-PD) in Parkinson’s disease patients with motor fluctuations: baseline characteristics

K. Kieburtz, W. Olanow, J. Krishnaswami, C. Resburg, F. Kerwood, C. Kenney (Rochester, NY, USA)

1:15pm-2:45pm

Transcranial direct current stimulation enhances consolidation of learning in Parkinson’s disease

S. Broeder, E. Nackaerts, E. Heremans, K. Cuypers, R. Meesen, G. Verheyden, A. Nieuwboer (Leuven, Belgium)

1:15pm-2:45pm

Tremor’s Glove – An Innovative Electrical Muscle Stimulation Therapy to Treat Intractable Tremor in Parkinson’s Disease Patients: A Randomized Sham-Controlled Trial

O. Jitkritsadakul, C. Thanawattano, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

1:15pm-2:45pm

Using an Objective Measure of Movement to Quantify Night Time Sleep

P. Farzanehfar, P. Churchward, M. Horne (Parkville, Australia)

1:15pm-2:45pm

Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis

C. Tarolli, K. Andrzejewski, M. Bull, S. Goldenthal, M. O'Brien, T. Simuni, G. Zimmerman, K. Biglan, E.R. Dorsey (Rochester, NY, USA)

1:15pm-2:45pm

Vitamin D and Clinical Phenotypes of Parkinson’s Disease

F. Jamal, G. Jackson, S. Moore, A. Sarwar (Houston, TX, USA)

1:15pm-2:45pm

Voice Therapy Normalizes Feedforward and Feedback Networks of the Speech Motor System

S. Narayana, C. Franklin, E. Peterson, D. Robin, P. Fox, L. Ramig (Memphis, TN, USA)

1:15pm-2:45pm

Wearing Off Frequency in Different Hoehn-Yahr Stages in Parkinson’s Disease

H. Cotur Levent, E. Bayram, M. Akbostanci (Ankara, Turkey)